Breaking News

Cobra Biologics, BioCancell Enter CTM Pact

By Kristin Brooks | March 3, 2014

Cobra to provide GMP manufacture and aseptic fill/finish of BC-821

Cobra Biologics and BioCancell have entered an agreement for the manufacture of BioCancell’s BC-821 cancer drug for clinical trials. The Phase I trial, scheduled to begin in 2015, will examine the use of BC-821 as a treatment for several cancer indications such as non-small-cell lung carcinoma, ovarian cancer, glioblastoma and liver metastasis.
Cobra will provide GMP manufacture and aseptic fill/finish of BC-821 plasmid DNA, before releasing it for clinical trials. Cobra’s DNA programs offer full regulatory support from a dedicated Quality Assurance (QA) team.
Peter Coleman, chief executive officer of Cobra Biologics, said, “Cobra has been manufacturing plasmid therapeutics and DNA vaccines for more than 16 years and I am delighted that we are able to announce this partnership with BioCancell. Our DNA platform process is based on Cobra’s pioneering heritage in gene therapy manufacturing and technology development.”

Related Contract Manufacturing:

blog comments powered by Disqus